Carmen D. Schweighofer

Author

The University of Texas MD Anderson Cancer Center

Also Known As

C. Schweighofer, C.D. Schweighofer, Carmen D Schweighofer, Carmen D. Schweighofer, Carmen Diana Schweighofer, Carmen Schweighofer

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center University of Cologne University Hospital Cologne Mayo Clinic Ludwig-Maximilians-Universität München

About

Carmen D. Schweighofer is an author at The University of Texas MD Anderson Cancer Center specializing in immunology, immunotherapy, and autoimmunity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	17
2	Cell Biology	1	1	17
3	Immunology	1	1	17
4	Molecular Genetics	1	1	17
5	Pathology	1	1	17

Carmen D. Schweighofer

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group Kirsten Fischer, Paula Cramer, Raymonde Busch, Journal of Clinical Oncology	2011	372
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia Barbara Eichhorst, Raymonde Busch, Stephan Stilgenbauer, Blood	2009	333
Consolidation with alemtuzumab improves progression‐free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission – long‐term follow‐up of a randomized phase III trial of the German CLL Study Group (GCLLSG) Carmen D. Schweighofer, Matthias Ritgen, Barbara Eichhorst, British Journal of Haematology	2008	101
Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG) Kirsten Fischer, Stephan Stilgenbauer, Carmen D. Schweighofer, Blood	2008	99
Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors Clemens‐Martin Wendtner, David M. Kofler, Christian Kurzeder, Blood	2002	79
Chronic Lymphocytic Leukemia With t(14;19)(q32;q13) Is Characterized by Atypical Morphologic and Immunophenotypic Features and Distinctive Genetic Features Yang O. Huh, Carmen D. Schweighofer, Rhett P. Ketterling, American Journal of Clinical Pathology	2011	43
Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results Of a Randomized German-French Cooperative Phase III Trial Carmen D. Schweighofer, Florence Cymbalista, Carolin Müller, Blood	2013	40
LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients Hatice Duzkale, Carmen D. Schweighofer, Kevin R. Coombes, Blood	2011	33
Due to low infection rates no routine anti‐infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine‐based first line therapy Barbara Eichhorst, Raymonde Busch, Carmen D. Schweighofer, British Journal of Haematology	2006	32
No Significant Clinical Benefit of First Line Therapy with Fludarabine (F) in Comparison to Chlorambucil (Clb) in Elderly Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Phase III Study of the German CLL Study Group (GCLLSG). Barbara Eichhorst, Raymonde Busch, Martina Stauch, Blood	2007	31

Page 1